The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1476
August 31, 2015
View Complete Issue         Table of Contents 2019 
A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
August 31, 2015 (Issue: 1476)
Immune globulin (IgG) has been available for administration intravenously once every 3-4 weeks or subcutaneously once daily, once weekly, or every 2 weeks for treatment of primary immunodeficiencies. Now the FDA has approved human immune...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Subcutaneous Immune Globulin (HyQvia) for Primary Immunodeficiency
Article code: 1476b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.